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ABSTRACT 
Patients with psoriasis are at an increased risk for depression. Despite this risk, many 
dermatology care providers do not screen for depression in practice, including providers at the 
target practice for this project. This evidence-based practice pilot project was purposed to 
increase dermatology providers’ assessment of depression in patients with psoriasis. This project 
involved implementing a depression screening protocol at one private dermatology practice and 
educating providers on the use of the protocol including the embedded depression screening tool, 
the Patient Health Questionnaire-9. The project leader used a quasi-experimental design and 
collected data utilizing retrospective chart reviews completed pre- and post-intervention. The 
measurable outcomes for this project included the number of depression screenings documented 
versus the number of patients with psoriasis seen during a 30-day period pre- and post-
intervention. This project revealed both clinical and statistical improvement of depression 
screening post-intervention supporting that provider assessment of depression in patients with 
psoriasis was enhanced with the implementation of a screening protocol. The results of this 
project have important implications for enhancing depression screening for patients with 
psoriasis in dermatology care settings.   
Keywords: Psoriasis, depression, suicidality, screening protocol, dermatology, Patient 
Health Questionnaire-9  
 
 
 
 
DEPRESSION SCREENING FOR PATIENTS WITH PSORIASIS  4 
IMPLEMENTATION OF A SCREENING PROTOCOL TO IMPROVE PROVIDER 
ASSESSMENT OF DEPRESSION IN PATIENTS WITH PSORIASIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 
Marlee Rachel Bryant 
ALL RIGHTS RESERVED  
DEPRESSION SCREENING FOR PATIENTS WITH PSORIASIS  5 
Dedication 
This scholarly project is dedicated to every person who has ever experienced depression 
or has been impacted by suicide in some way, shape, or form – to every mother, father, 
grandparent, sibling, spouse or significant other, friend, coworker, or child who has lost a loved 
one to suicide. Depression is a disorder. It is not something to be taken lightly and certainly not 
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on the importance of addressing depression and other mental health disorders for all ages and all 
patient populations.  
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Introduction 
Psoriasis (PSO) is a common chronic inflammatory skin condition characterized by skin 
lesions that can cause pain, itching, burning, and irritation (Menter & Ryan, 2017). There are 
varying degrees of severity in PSO, which can be further complicated by non-cutaneous 
comorbidities such as inflammatory arthritis and cardio-metabolic disorders (Singh, Taylor, 
Kornmehl, & Armstrong, 2017). The burden of PSO as a disease goes far beyond dermatologic 
considerations. The physical, psychosocial, and financial burden of PSO can have a profound 
negative impact on a patient’s quality of life (QoL) and place the patient at a significant risk for 
psychological conditions such as depression (Singh et al., 2017).  
Though many dermatology practitioners acknowledge the risk of depression in patients 
with dermatologic diseases, it is uncertain how often dermatologists screen at-risk patients for 
secondary psychiatric disorders (McDonald, Shelley, & Jafferany, 2018). Clinical practice 
guidelines and expert recommendations on treating and managing PSO acknowledge the 
importance of addressing comprehensive care for this patient population including the 
assessment of depression (Burden et al., 2010). This evidence-based practice (EBP) pilot project 
provided a depression screening protocol and education on the use of the protocol to providers in 
a dermatology clinic in efforts to enhance the quality of care delivered to patients with PSO.  
Background 
Background on Psoriasis  
Epidemiology. PSO is one of the most common chronic dermatologic conditions and 
affects more than 125 million people worldwide (Menter & Ryan, 2017). It is estimated that 7.4 
million adults in the United States (U.S.) have PSO (Rachakonda, Schupp, & Armstrong, 2014). 
The reported incidence is approximately 59.9 per 100,000 people per year (Menter & Ryan, 
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2017). In adults, men appear to have a higher incidence of the disease than women, and the 
prevalence of PSO is lower in non-Caucasians (Menter & Ryan, 2017).   
Characteristics and risk factors. There are many different types of PSO. The most 
common type is plaque-type psoriasis or psoriasis vulgaris, which accounts for 90% of the cases 
of PSO (Menter & Ryan, 2017). PSO can occur on any part of the body but commonly affects 
the scalp, trunk, and extensor surfaces which are often visible parts of the body (Menter & Ryan, 
2017). Some notable risk factors for PSO include family history, infection, certain medications, 
stress, smoking, alcohol use, sunburn, and trauma (Menter & Ryan, 2017).  
Physical impact. Plaque psoriasis generally causes well-demarcated symmetrical 
erythematous plaques with variable adherent scaling and thickness typically involving elbows, 
knees, trunk, scalp, sacrum, buttocks, and genitals (Menter & Ryan, 2017). Many people with 
chronic PSO will report intermittent disease exacerbations with pain, itching, and burning 
(Menter & Ryan, 2017). Though predominately affecting the skin, PSO can have a greater health 
impact than what can be seen by the human eye. Due to the nature of systemic inflammation, 
PSO is associated with an increased prevalence of cardio-metabolic diseases such as 
atherosclerotic cardiovascular disease, diabetes, obesity, and future vascular events (Menter & 
Ryan, 2017). In addition to these serious comorbidities, psoriatic arthritis (PsA) occurs in up to 
30% of people with PSO and can cause significant disability (Longo, Ritchlin, Colbert, & 
Gladman, 2017).  
Psychosocial impact. PSO by nature affects the appearances of individuals and as 
mentioned, is often present on parts of the body that are visible to others (Nazik, Nazik, & Gul, 
2017). Many patients with PSO fear stigmatization because of their disease and report that their 
condition negatively impacts their body image and sexuality (Hrehorów, Salomon, Matusiak, 
DEPRESSION SCREENING FOR PATIENTS WITH PSORIASIS  15 
Reich, & Szepietowski, 2012; Nazik et al., 2017). Some of the most common feelings of 
stigmatization described by patients are the anticipation of rejection and feelings of guilt and 
shame (Hrehorów et al., 2012). Many people also report that their PSO affects their ability to 
perform daily activities (Nazik et al., 2017).  
Financial impact. An additional burden of PSO is the financial impact of patient costs 
associated with the disease. Successful treatment and management of PSO is often associated 
with increased healthcare resource utilization and increased patient costs (Yu et al., 2009). 
Consequently, on average, a patient with PSO will spend $11,498 over a lifetime for the relief of 
symptoms (Brezinski, Dhillon, & Armstrong, 2015). Newer long-term medications on the market 
for PSO can cost patients as much as thousands of dollars each month. With respect to the 
potential physical, emotional, psychosocial, and financial impact of PSO, there are comparable 
degrees of disability caused by PSO to other chronic diseases such as diabetes, heart disease, and 
cancer (Burden et al., 2010). 
Background on Depression  
Epidemiology and disease definition. In the U.S., major depression is one of the most 
common psychological disorders (National Institute of Mental Health [NIMH], n.d.). It is 
estimated that 16.1 million adults ages 18 and older had at least one major depressive episode in 
the past year, accounting for 6.7% of adults in the U.S. (NIMH, n.d.). According to the 
diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders V (DSM-
5), major depressive disorder (MDD) consists of five or more specific symptoms that must be 
present for at least two weeks and signal a change from previous functioning (American 
Psychiatric Association [APA], 2013). Some of these symptoms include a depressed mood, 
diminished interest or pleasure in activities, significant unintentional weight loss or weight gain, 
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a decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation, fatigue or 
loss of energy, feelings of worthlessness, diminished concentration, and recurrent thoughts of 
death (APA, 2013).  
Impact of depression as a disease. In the U.S. and worldwide, depression has indirect 
and direct effects on morbidity and mortality (Smithson & Pignone, 2017). Significant available 
research demonstrates the negative effects of depression on an individual’s quality of life 
(Sivertsen, Bjørkløf, Engedal, Selbæk, & Helvik, 2015). Furthermore, MDD accounted for an 
economic burden of more than $210 billion in 2010 alone (Greenberg, Fournier, Sisitsky, Pike, 
& Kessler, 2015). In efforts to reduce morbidity, mortality, and healthcare costs associated with 
depression, healthcare providers play an important role in identifying patients with depression 
and those at risk for mental health disorders.  
Depression and psoriasis. The risk of depression amongst patients with PSO is well-
documented; however, the exact relationship between the two is still unknown (Singh et al., 
2017). According to Dowlatshahi, Wakkee, Arens, and Nijsten (2014), patients with PSO are 1.5 
times more likely to have depression and more than 4 times as likely to use antidepressants as 
patients without PSO. A recent meta-analysis study reports that patients with PSO have a 
significantly higher likelihood of suicidal ideation, suicide attempts, and completed suicides 
(Singh et al., 2017). Patients with PSO who suffer from PsA have been found to be at an even 
greater risk for depression than those without the comorbidity (McDonough, 2014). The 
knowledge of the risk of depression and suicidality in patients with PSO points to a need for 
appropriate screening methods in practice for early identification and treatment of depression for 
this patient population.  
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Background on Depression Screening 
Use of screening. Healthcare providers play an important role in assessing their patients 
for depression. Depression screening is not a new concept, and a growing body of literature 
supports the benefits of screening in combination with resources for disease management in the 
treatment of depression (Smithson & Pignone, 2017). Screening patients with chronic disease for 
depression is not a new consideration either and is well documented in patients with other 
chronic diseases such as chronic obstructive pulmonary disease and congestive heart failure 
(Julian et al., 2009; Buckley, 2015).  
Currently, the U.S. Preventative Service Task Force (USPSTF) recommends depression 
screening for all adults and especially for those adults with chronic disease (USPSTF, 2016). 
While primary care offices are generally the target areas for systematic depression screening, 
rates of depression screening in primary care remain low (Akincigil & Matthews, 2017). 
Specialty care providers must not assume depression is being addressed in primary care and 
should take this into consideration when caring for at-risk patients. 
Challenges with screening. Though depression screening tools offer many benefits, 
barriers to utilizing depression screenings in practice exist. Some cited barriers in utilizing 
depression screenings are time constraints, competing demands, and prior knowledge about the 
patient’s depression status (Fuchs et al., 2015).  Knowledge regarding the barriers in using 
depression screening tools in dermatology is limited (McDonald et al., 2018). Potential barriers 
may include a lack of clear guidelines, lack of time, or perception that secondary psychiatric 
disorders, such as depression, are outside of the dermatology domain (McDonald et al., 2018). 
This EBP project aims to utilize a protocol that incorporates an already validated depression 
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screening tool that can be delivered quickly to minimize barriers to the implementation of 
depression screening at the target dermatology practice.  
Opportunities for the Project 
There are many opportunities for this EBP project. Currently, depression screenings are 
recognized for reimbursement by Medicare and some private insurances in primary care on an 
annual basis (Savoy & O'Gurek, 2016). Codes for annual depression screenings generate 
approximately $15-$18 per patient per year (Savoy & O'Gurek, 2016). With that being said, 
specialty care providers, such as those in dermatology, currently have little financial incentive to 
perform depression screening. This presents a problem as some patients are often only or at least 
more frequently seen by specialty care providers, and depression screening in primary care 
remains low (Akincigil & Matthews, 2017). This project may help to further demonstrate the 
benefits and importance of depression screening for patients with chronic illnesses in specialty 
care areas like patients with PSO in dermatology.  
This EBP project may also help to improve the care delivered to patients with PSO at the 
target dermatology practice. Though this project did not look specifically at patients who screen 
positive for depression or how patients identified with depression were managed, providers who 
utilize the depression screening protocol may identify practice patients who could benefit from 
psychiatric services to promote overall health and could determine high-risk patients for 
depression not otherwise recognized. This notion has implications for improving comprehensive 
care and enhancing collaboration among healthcare specialties such as between dermatology, 
psychiatry, and primary care services. 
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Problem Statement 
Though patients with PSO are at an increased risk for depression, many providers do not 
screen this population for depression in practice, which may lead to failure in the recognition of 
patients with depression requiring treatment.   
Purpose of the Project 
The purpose of this project is to increase dermatology providers’ assessment of 
depression in patients with PSO. The significance of increasing depression screening in patients 
with PSO is to allow for early recognition and referral for treatment of this common 
psychological comorbidity.  
Clinical Question 
Will the implementation of a depression screening protocol and education on the use of 
the protocol enhance provider assessment of depression in patients with PSO?   
Population 
The target population for this project was providers who care for patients with PSO at 
one private dermatology practice. 
Intervention 
The primary intervention of this project was the implementation of a depression 
screening protocol and education for the providers on the use of the protocol in practice. 
Comparison 
The project leader utilized chart reviews to compare depression screening prior to 
(control group) and after the intervention (comparison group).  
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Outcomes 
The primary outcome was to increase provider assessment of depression in patients with 
PSO by increasing the use of depression screening (PHQ-9) for this patient population. 
Literature Review 
Search Strategy 
The project leader completed a search of CINAHL, PUBMED, JAMA, and ProQuest. 
The keywords used for the literature review were psoriasis, depression, suicidality, screening, 
depression protocol, PHQ-9, dermatology, comorbidities, self-esteem, body image, 
stigmatization, and quality of life. All articles were limited based on those written in the last 
fourteen years including a date range from 2004-2018. A majority of these articles were written 
in the last six years. All articles gathered were in the English language, and a majority were full-
text articles with abstracts. The project leader reviewed over 70 abstracts for relevance and 
selected 22 articles for the literature review.  
Critical Appraisal 
 Evidence demonstrating the links between depression and PSO as well as the factors 
contributing to the risk of depression in patients with PSO were important focuses of this review. 
Besides why patients with PSO are at risk for depression, implications for depression screening 
in dermatology are supported by available research including the depression screening tool 
embedded in the protocol implemented for this project. The project leader reviewed and ranked 
the literature according to strength utilizing a rating system for the hierarchy of evidence 
(Melnyk & Fineout-Overholt, 2015). Out of the 22 studies included, there were two systematic 
reviews and meta-analyses, nine controlled trials without randomization, six case-controls or 
cohort studies, two single descriptive studies, and three expert opinions. Common limitations 
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among the available research included small sample sizes for controlled trials, convenience 
sampling, and non-randomization of subjects (see Appendix A for evidence table).  
Psychosocial Factors Linked to the Risk of Depression in Patients with Psoriasis  
 Throughout the literature, research studies highlighted multiple psychosocial factors 
contributing to the risk of depression in patients with PSO. The most common factors identified 
throughout the review were self-esteem, body image, stigmatization, and perceived quality of 
life. In the subsequent paragraphs these factors are discussed as they relate to patients with PSO.  
Self-esteem and body image. As compared to patients without the disease, patients with 
PSO have been found to have lower levels of satisfaction with body image and self-esteem 
(Nazik et al., 2017). In particular, one study found that women with PSO report stronger beliefs 
in the influence and importance of body image or physical appearance on self-worth (Wojtyna, 
Lakuta, Marcinkiewicz, Bergler-Czop, & Brezezinska-Wcislo, 2016). Recognizing the 
relationship between body image and depression, researchers have found that improving body 
image in patients with PSO may contribute to the prevention of depression, especially in women 
(Wojtyna et al., 2016).  
Stigmatization. Patients with PSO may fear stigmatization because of the appearance of 
their disease. Hawro et al. (2017) acknowledged PSO and stigmatization but aimed to more 
clearly define the links among lesion distribution and severity of the disease to stigmatization. 
They found that PSO lesions on the back of hands were related to higher levels of stigmatization 
(Hawro et al., 2017). Furthermore, people who were not able to hide lesions by clothing reported 
higher levels of stigmatization and women demonstrated a greater sensitivity to stigmatization 
(Hawro et al., 2017). In this same study, the strongest predictor of QoL impairment was 
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stigmatization suggesting that greater feelings of stigmatization result in reductions in an 
individual’s reported QoL (Hawro et al., 2017).  
Quality of life. PSO can be a debilitating skin disease with a significant negative impact 
on health-related QoL. As previously cited, degrees of disability caused by PSO may be similar 
to other chronic diseases such as diabetes, heart disease, and cancer (Burden et al., 2010). A 
large portion of the burden on the QoL of patients with PSO centers on the psychosocial burden 
of the disease. Throughout the literature search, multiple studies on PSO and QoL highlighted 
psychosocial factors as having a negative impact on patients with PSO (Hawro et al., 2017; 
Nazik et al., 2017; Wojtyna et al., 2016). For example, one study found that patients with PSO 
have greater levels of loneliness and social isolation compared to those without the disease 
translating into reductions in reported QoL (Kouris et al., 2016). Acknowledging decreased QoL 
reported in patients with PSO, Korman, Zhao, Pike, and Roberts (2016) further studied the 
relationship among severity of PSO and QoL and found that patients with more severe disease 
experienced greater reductions in reported QoL. 
Factors linked to depression. A noteworthy study in Poland examined the importance of 
psychosocial factors in relation to depressive symptoms in patients with PSO (Wojtyna et al., 
2016). Certain factors addressed were gender, the age of onset of disease, the extent of disease, 
perceived social support, subjective distress, and beliefs regarding the importance and influence 
of appearance (Wojtyna et al., 2016). At the conclusion of the study, researchers found that 
depressive symptoms and distress were higher in women than in men with women placing 
greater value in appearances (Wojtyna et al., 2016). Despite these differences, psychological 
distress was an important risk factor for depression in both men and women regardless of disease 
severity (Wojtyna et al., 2016). Such findings have important implications for clinicians to take 
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into consideration. Clinicians should assess patients with PSO for their subjective levels of 
distress and recognize the role this chronic disease plays in psychological health (Wojtyna et al., 
2016). 
Risk of the Additional Burden of Comorbidities in Patients with Psoriasis  
Multiple comorbidities are associated with PSO including PsA, obesity, hypertension, 
malignancies, metabolic syndrome, and cardiovascular disease (Feldman et al., 2017). Costs for 
medical conditions associated with PSO are estimated at an additional $36.4 billion annually 
(Feldman et al., 2017). Comorbidities can place significant distress among patients with PSO 
adding to the potential burden of disease. 
In efforts to better understand the additional burden of PsA as a comorbidity, one study 
found that patients with PsA reported poor work productivity, worse pain and fatigue, and a 
greater morbidity burden than those with PSO alone (Strober et al., 2017). It should also be noted 
that in the same study 24% of patients with PSO and PsA reported depression as opposed to 16% 
of those with PSO alone (Strober et al., 2017). 
Increased risk for comorbidities in patients with PSO warrants greater medical 
monitoring to ensure overall health and quality of life (Kimball et al., 2008). The National 
Psoriasis Foundation suggests dermatologists must play an active role in educating patients on 
the potential negative health effects of their PSO as they relate to other aspects of their health 
and consider screening tests, preventative exams, and referrals for comorbidities (Kimball et al., 
2008).  
Risk of Depression in Patients with Psoriasis  
A link between PSO and depression exists throughout the literature. In a hospital-based, 
case-control study in Iran, patients with PSO reported significantly higher degrees of depression 
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than the control group, supporting a relationship between PSO and depression (Golpour et al., 
2012). Cohen, Martires, and Ho (2016) investigated the association of PSO and MDD in the U.S. 
population and found that 16.5% of patients with PSO met the criteria for a diagnosis of MDD.  
A meta-analysis study on the prevalence of depressive symptoms and clinical depression 
in patients with PSO further supports the relationship between PSO and depression by revealing 
that more than 10% of patients with PSO suffer from clinical depression and roughly 20% have 
depressive symptoms (Dowlatshahi et al., 2014). Another more recent meta-analysis study 
regarding the suicidality of patients with PSO found that compared to the general population, 
patients with the disease are at increased risk for all aspects of suicidality (Singh et al., 2017).   
In comparing depression in patients with other dermatologic diseases such a melanoma 
and allergies, patients with PSO have an increased risk for psychiatric comorbidities and suicidal 
ideations (Pompili et al., 2017). Of the patients with PSO, one study found that the risk for MDD 
is significantly higher in women and patients with a severe clinical disease, comorbidities such 
as PsA, and previous psychiatric conditions (Lamb et al., 2017). It should also be noted that 
patients with PSO who are younger (age < 20) at the age of disease onset are often significantly 
more depressed than patients with late-onset PSO (Remröd, Sjöström, & Svensson, 2013). The 
literature supports that patients with PSO are at an increased risk for depression, and healthcare 
providers should take this into consideration when caring for this population.  
Implications for Depression Screening in Dermatology  
The medical community generally recognizes the common occurrence of psychiatric 
disorders among patients with physical diseases or chronic illnesses. Recently more studies have 
demonstrated the prevalence of depression specifically among patients with dermatologic 
diseases (AlShahwan, 2015). But though there are documented risks of depression for patients 
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with dermatologic diseases, there is limited literature regarding the assessment of depression in 
clinical dermatologic practice (McDonald et al., 2018). In the research studies that do address 
depression screening in dermatology practice, assessment techniques included provider clinical 
judgment, questionnaires, diagnostic criteria, and disease codes (Korman et al., 2016). 
McDonald, Shelley, and Jaffernany (2018) acknowledge that patients and dermatologists could 
benefit from a screening tool to identify secondary psychiatric conditions and recommend 
standardized screening for depression and suicidal ideation.  
While questionnaires are cited to be more commonly used in research studies, the most 
commonly used method for assessing depression in patients with PSO in clinical practice is 
clinician judgment (Dowlatshahi et al., 2014). The sensitivity and specificity of dermatologists’ 
clinical judgment for depression in patients with PSO has been found to be 60% and 21% 
(Richards, Fortune, Weidmann, Sweeney, & Griffiths, 2004). The same study found that 
agreement between dermatologists and patients with PSO regarding the presence of 
psychological distress was low (Richards et al., 2004). Beyond this, the study also found that the 
majority of times that patients were identified as being depressed, no further actions were taken 
(Richards et al., 2004).  
PHQ-9 For Depression Screening 
Screening tools have been established as a cost-effective intervention to promote early 
identification and treatment of depression used in a variety of healthcare settings (Jiao, Rosen, 
Bellanger, Belkin, & Muennig, 2017; Wilkinson, Anderson, & Wheeler, 2017). This project 
utilized the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a brief and useful 
multipurpose instrument used to screen, diagnose, monitor, and measure depression severity 
(Pfizer, 1999).  
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While controversy exists over which depression screening tool is most reliable in clinical 
practice, the PHQ-9 is a validated instrument in screening for MMD and depressive symptoms 
(Suzuki, Kumei, Ohhira, Nozu, & Okumura, 2015). In one of the largest validation studies on the 
PHQ-9, the sensitivity and specificity of the PHQ-9 was 74% and 91% (Arroll et al., 2010). 
Compared to shortened versions of the PHQ-9, this tool is more specific for identifying 
depression (Arroll et al., 2010). Unfortunately, a review of the literature revealed limited studies 
on the use of depression screening tools specifically in dermatology practices. Though this gap in 
the literature exists, the PHQ-9 has been used in studies for both depression and PSO (Lakshmy, 
Balasundaram, Sarkar, Audhya, & Subramaniam, 2015). This notion highlights the need for 
enhanced routine screening of patients with PSO as early detection of depression as a psychiatric 
comorbidity (Lakshmy et al., 2015; Cohen et al., 2016).  
Depression Screening Protocols 
Screening patients for depression is important, but what providers do with positive 
screenings after is just as important. To expedite the identification and treatment of depression 
among different groups of patients, depression screening protocols are often used in practice 
settings. One study examined the use of a depression screening protocol among patients with 
acute stroke to determine if the protocol improved early detection and treatment of post-stroke 
depression (McIntosh, 2017). The study utilized the PHQ-9 and found that the protocol improved 
early detection and treatment of depression prior to hospital discharge for patients post-stroke 
(McIntosh, 2017).  
Another study examined the role of training in implementing a depression screening and 
treatment protocol in outpatient internal medicine clinics (Loeb, Sieja, Corral, Zehnder, Guiton, 
& Nease, 2015). Loeb et al. (2015) found that training attendance was associated with increased 
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compliance with protocol procedures, highlighting the importance of training in the 
implementation of practice changes. Considerations for this scholarly project recognize the value 
of a screening protocol over a screening questionnaire alone and education on the use of the 
protocol to promote appropriate use. Though this project did not specifically look at what 
providers did with any positive depression screenings, the protocol did make recommendations 
for follow up screenings based on individual PHQ-9 scores.   
Conceptual Framework 
The conceptual framework utilized in this EBP pilot project was the Iowa Model of 
Evidence-Based Practice to Promote Quality Care (Iowa Model Collaborative, 2017). This 
model is used throughout nursing research and is an effective model in leading an EBP change 
(Hall & Roussel, 2014). The Iowa Model is a step-wise approach to addressing important steps 
in a clinical question and determining evidence available to support clinical decisions (Hall & 
Roussel, 2014). This model served as a map regarding the course of actions taken throughout the 
implementation of this project to enhance provider assessment of depression in patients with 
PSO.  
Project Triggers 
According to the Iowa Model, triggers must first be identified (Hall & Roussel, 2014). 
The knowledge-focused trigger identified in this project was that patients with PSO are at a 
significant risk for depression and suicidality (Singh et al., 2017). Many dermatology practices, 
including the target private practice for this project, do not screen patients with PSO for 
depression. This trigger presented an opportunity for improvement in comprehensive patient care 
by assessing psychological health often not previously addressed.  
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Organization Priority  
This project addressed a priority for the private practice in which this project was 
intended for implementation. The dermatology practice in question sees a variety of patients with 
varying degrees of PSO on a daily basis. As a part of the mission statement, the practice strives 
to offer patient-centered comprehensive care. Depression screening addresses psychological care 
which is an important aspect of comprehensive care. Providing necessary supplies and educating 
providers on the use of a depression screening protocol for patients with PSO may help the 
practice to provide higher quality comprehensive care. The practice agreed that this project was 
important and supported it. 
Project Team and Research Assembly 
The next steps of the Iowa Model include forming a team, assembling relevant research, 
critiquing and synthesizing the research, and determining a sufficient base for the project (Hall & 
Roussel, 2014). The team for this practice project consisted of one Doctor of Nursing Practice 
(DNP) student or project leader, one graduate faculty advisor or project chair, and one provider 
at the target practice. As outlined in the literature review, there was sufficient evidence for this 
practice project and an identified need for depression screening tools in dermatology practice. 
Though the use of depression screening tools in dermatology practice is limited, the screening 
method chosen for this practice project has been used in such a setting, and clinical guidelines 
call for a greater assessment of depression in patients with PSO.   
Project Design, Piloting Change, and Evaluation 
The fifth step of the Iowa Model calls for designing and piloting the practice change. This 
EBP project involved implementing a depression screening protocol for patients with PSO at a 
small private dermatology practice and educating providers on the use of the clinical tool. The 
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dermatology providers caring for patients with PSO were the target population for this practice 
project. Prior to piloting the practice change, the project leader developed an evaluation plan and 
gathered baseline information on the average number of patients with PSO seen at the office as 
well as provider use of depression screening pre-intervention. The promotion of practice change 
adoption took place at one monthly provider meeting, and the DNP student was available 
throughout the implementation phase by email or phone to answer questions from providers and 
staff on the suggested practice change. Approximately two months after the suggested practice 
change was introduced, the project leader gathered data on whether or not the intervention 
improved the assessment of depression in patients with PSO. Whether or not this practice change 
is appropriate for long-term adoption will depend on the providers’ perceptions of the usefulness 
of the tool in practice and addressing any barriers to long-term implementation.  
Methodology 
Project Design 
This was an EBP pilot project that consisted of implementing a depression screening 
protocol for providers in dermatology to utilize in practice when caring for patients with PSO 
(See Appendix F for depression screening protocol). This project took place over two months at 
a private dermatology practice that sees approximately 15 patients with PSO per week. The 
implemented screening protocol utilized one validated depression screening tool, the PHQ-9 (See 
Appendix G for screening tool). As a quasi-experimental approach, the design of this project 
allowed for the project leader to assess the impact of the intervention on provider assessment of 
depression in patients with PSO by looking at pre- and post-intervention measures.  
Because a screening protocol offers providers recommendations and interventions based 
on patient outcomes, the project leader chose a screening protocol over the implementation of a 
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depression questionnaire alone. This was an important consideration to help the project team 
who recognized the gravity of depression and potential for positive screening warranting further 
assessment. Though this project did not focus on how many positive screenings there were, a 
plan on what to do if depression was identified was a significant consideration to the 
implementation of this project at the target practice. A written document with suggestions for 
how to address positive screenings and contact information for local mental health resources was 
provided to each participating provider. Though the project leader offered suggestions, the 
providers were able to address any positive depression screenings at their own discretion.  
Adapted from Korman et al. (2016), the depression screening protocol encouraged 
providers to screen patients with PSO at initial diagnosis or those patients previously diagnosed 
with PSO that have never been screened for depression at the office. The original protocol 
suggested the Patient Health Questionnaire-2 (PHQ-2) be used initially, which is a shortened 
version of the PHQ-9. In efforts to streamline the depression screening protocol for the target 
practice and for the purposes of this project, the project leader removed the PHQ-2 from the 
protocol and recommended the PHQ-9 as the only screening questionnaire to be used.  
According to the protocol, patients who scored less than or equal to ten on the PHQ-9 
should be recommended for repeat depression screening in one year (Korman et al., 2016). For 
those patients who scored between eleven and fourteen, a repeat PHQ-9 was recommended at the 
following visit (Korman et al., 2016). Lastly, those patients who scored greater than or equal to 
fifteen were recommended for referral for psychiatric evaluation with repeated PHQ-9 screening 
suggested at the next office visit (Korman et al., 2016). Though patients who scored fifteen or 
greater were recommended for referral based on the protocol, providers were made aware that 
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any patients identified with depression could also be referred and that referrals were ultimately 
up to the discretion of the individual provider.  
This project did not address specific patients directly. The intervention did not look at 
how many positive depression screens there were or how treatment was carried out, but rather 
how having this protocol available in practice and educating providers on the use of the protocol 
impacted provider assessment of depression in patients with PSO.  
Measurable Outcomes 
Measurable outcomes were important to this EBP project as they helped to define how 
the depression screening protocol and provider education impacted the assessment of patients 
with PSO for depression at the project site. The measurable outcomes for this project were the 
number of patients with PSO screened for depression compared to the total number of patients 
with PSO seen at the office pre-and post-implementation of the depression screening protocol. 
The time frame of interest was a 30-day period before the intervention and a 30-day period after 
the intervention. The number of depression screenings documented and the total number of 
patients with PSO seen during the pre-intervention 30-day time frame by all participating 
providers served as the before measures. The number of depression screenings documented and 
the total number of patients with PSO seen during the post-intervention 30-day time frame by the 
participating providers served as the after measures. 
Setting 
The setting for this EBP project was a private dermatology practice caring for patients 
with a variety of dermatologic needs. The practice strives to provide comprehensive and quality 
healthcare which aligned with this project’s aim. The organizational structure of the practice 
includes physician practice owners, managers, providers, a nurse, clinical assistants, and non-
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clinical staff. The clinical assistants and the nurse involved in direct patient care likely played an 
important role in providing patients with depression screening questionnaires based on identified 
depression screening needs as determined by the providers. The support of practice 
administrators was crucial to the success of the project implementation. 
Population 
The target subjects for this EBP project were nine dermatology providers within the same 
dermatology practice including four physicians and five advanced practice providers. The 
advanced practice providers consisted of four physician assistants and one nurse practitioner. 
Though there were nine providers at the practice, two physicians and one physician assistant 
were excluded from this project as they do not manage care for patients with PSO but instead 
work in surgical or aesthetic areas of the practice. Each of the other six providers serve different 
roles within the practice but all six provide care for patients with PSO, some more than others.  
Ethical Considerations  
For the protection of subject rights, no personal information regarding the participating 
providers or place of practice was disclosed. The participating providers were also not penalized 
for choosing not to screen patients with PSO for depression. Though the office also cares for 
pediatric patients, the project leader told providers to avoid screening anyone under than age of 
18 using the protocol provided, and no data was collected from patients under the age of 18 or 
over the age of 90. Providers were not compensated for participating in the project; however, the 
project leader provided a meal to the practice at the conclusion of the project in gratitude for 
provider and staff participation.  
 The project leader has completed research ethics training to ensure protection of human 
subjects (see Appendix C for CITI certificate). The committee-approved project proposal was 
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submitted to Liberty University’s (LU’s) Institutional Review Board (IRB) and received 
exemption from further review as this project fell under an exemption for involving the 
collection of information in such a manner by the investigator that subjects cannot be identified, 
directly or through identifiers linked to the subjects (see Appendix B for IRB approval 
documentation). There was no IRB at the project site. Though LU’s IRB waived formal written 
consent from individual providers for this project, the project leader obtained written consent 
from the practice administration for project implementation and use of the electronic medical 
record (EMR) for data collection (see Appendix D for site approval).  
Data Collection 
The project leader performed retrospective chart reviews for a 30-day period four weeks 
before the intervention and four weeks after the intervention to obtain data for this project. The 
project leader reviewed charts for patients with a diagnosis of PSO as well as the documentation 
of depression screening in the form of the PHQ-9. The number of patients with PSO who were 
seen within the 30-day time frames pre- and post-intervention and the number of depression 
screenings, in the form of the PHQ-9, were recorded.  
Though the project leader performed chart reviews on patients throughout this project, 
the leader did not utilize any identifying patient or provider information. As mentioned, the 
primary focus of this project was whether or not provider assessment of depression was 
enhanced with the implementation and education of a depression screening protocol rather than 
how this screening would affect patients with PSO. The project leader reviewed charts during 
data collection based on those patients with PSO cared for by participating providers, equal or 
greater than 18 years old and equal or less than 90 years old, and those seen at the office within a 
30-day period prior to and following the intervention. The data was grouped as “pre-
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intervention” or “post-intervention” according to the date of the visit and “yes” or “no” for 
whether or not depression screening was documented. This data was later coded for statistical 
analysis as the following: “pre-intervention” = 1, “post-intervention” = 2, “no” = 1, and “yes” 
=2.  
There was no personal health protected information written or stored outside of the EMR 
that was used to track the number of patients seen with PSO and the number of depression 
screenings documented. The data collection was reserved to the project leader who upheld 
compliance with the Health Information Portability and Accountability Act (HIPAA). The data 
was kept on a password-protected computer only accessible to the project leader in a Microsoft 
Excel® spreadsheet. This spreadsheet will be kept for three years following the completion of 
the project. After three years, the electronic documents will be placed into the computer trash bin 
and permanently removed from the bin in order to support further privacy.  
Tools 
The main tools necessary for this EBP project were the depression screening protocol and 
embedded screening questionnaire, the PHQ-9. The project leader gave the providers copies of 
the tools and placed more copies in most exam rooms within a file folder under a tab labeled 
“Depression Screening.” Along with these tools, the project leader also provided laminated 
copies of the suggested course of action for patients identified with depression and handouts on 
how to interpret PHQ-9 results to the participating providers.  
In order to complete the chart reviews, the project leader used the practice’s established 
EMR. Sorting tools within the office’s established EMR allowed for the identification of patients 
seen within a specified time frame. The project leader reviewed charts for all participating 
providers during each 30-day pre- and post-intervention period for a diagnosis of PSO and 
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whether or not depression screening was documented. Microsoft Excel® was the data collection 
tool used to manually track the date of visits for patients with PSO and whether or not screening 
was documented in the EMR. This tool was accessed on a password protected computer only 
accessible to the project leader.  
Intervention 
The intervention for this EBP project was the depression screening protocol in 
combination with education to providers on use of the screening tool in practice (See Appendix F 
for depression screening protocol). This protocol was adapted and modified from an article on 
the evaluation and management of depression in patients with PSO (Korman et al., 2016). The 
tool or questionnaire utilized in the depression screening protocol, the PHQ-9, is publicly 
available for providers to use in practice as well as in this project (Pfizer, 1999).  
The intervention, including the depression screening protocol and education to providers 
on the use of the protocol, was delivered at one monthly provider meeting. The project leader 
educated providers on the prevalence of depression among patients with PSO, the depression 
screening protocol itself including the embedded PHQ-9, and where to find resources for this 
protocol at the office. In addition to these topics, the project leader gave providers the suggested 
course of action to take for any patients identified with depression and contact information for 
local mental health resources. The day following the provider meeting marked the introduction 
of the protocol in practice.  
Timeline of Project Phases 
Preparation. The preparation for this project consisted of identifying the problem-focused 
triggers, determining if the topic was a priority for the organization, forming a team, assembling 
and synthesizing research, and determining if there was sufficient research to base the practice 
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change. The steps of this project’s preparation reflected the conceptual framework used, the Iowa 
Model of Evidence Based Practice. The activities that occurred during the preparation phase 
included the following:  
• On September 4th, 2017, the project leader presented the project proposal to a practice owner 
and key stakeholder. 
• On December 20th, 2017, the project leader delivered the project proposal to the project chair 
and approval was given with minimal edits.  
• On April 5th, 2018, the project leader submitted the project proposal to LU’s IRB.  
• On May 11th, 2018, LU’s IRB approved the project proposal.  
• On June 1st, 2018, the project leader formed the project team. 
 Implementation.  After preparation and according to the conceptual framework, the 
implementation phase consisted of the introduction of the depression screening protocol and 
education to the providers on the use of the protocol. This also consisted of providing necessary 
supplies for the providers to use for the depression screening protocol in practice. The activities 
that occurred during this stage included: 
• On June 7th, 2018, the project leader placed copies of the depression screening protocol, 
PHQ-9’s, and other protocol documents in most exam rooms for the providers to use or 
within the shared work areas. 
• On June 7th, 2018, the project leader delivered the intervention at one monthly provider 
meeting. 
• June 8th, 2018, marked the introduction of the protocol in practice.  
• On July 8th, 2018, the 30-day window period post-intervention began.  
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• August 1st – August 6th, 2018, the project leader performed chart reviews for pre- and post-
intervention. 
• On August 6th, 2018, the 30-day window period post-intervention ended.  
 Evaluation.  Following the Iowa Model of EBP, the project leader evaluated the 
intervention to determine if a change in practice occurred. The activities that occurred during the 
evaluation stage included the following:  
• On August 6th, 2018, the project leader completed all pre-and post-intervention chart reviews. 
• On August 7th, 2018, the project leader completed the data analysis.  
• On October 1, 2018, the project leader will disseminate project results to the providers at the 
practice.  
Data Analysis 
 The data analysis for this EBP project took place using IMB® Statistical Package for the 
Social Sciences® (SPSS®), Version 25.0, to generate statistical and descriptive results. Because 
the data was nominal in nature, the data collected for this project best fit statistical testing 
utilizing the Fisher’s exact test of independence because of the small sample size (Rao, 2017). 
This nonparametric statistical test is used when one wants to determine if the proportions for one 
variable are different among values of the other variable (Rao, 2017). The project leader 
categorized the data as “pre-intervention” or “post-intervention” and as “no” or “yes” for 
whether or not depression screening was documented. For analysis purposes, the project leader 
coded the data in order to run the statistical test (“pre-intervention” = 1, “post-intervention” = 2, 
“no” = 1, and “yes” = 2). For the Fisher’s Exact test, the null hypothesis was that there was no 
change in the number of depression screenings documented for patients with PSO from pre-
intervention to post-intervention (H0: p1 = p2). The alternative hypothesis was that there was an 
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increase in depression screenings documented for patients with PSO from pre-intervention to 
post-intervention (H1: p1 < p2). An alpha of 0.05 was used. For descriptive statistics, the project 
measures were reported as ratios and percentages for comparison of pre- and post-intervention 
outcomes. Besides SPSS®, the project leader used Microsoft Excel® to generate figures and a 
table for the visualization of results pre- and post-intervention.  
Feasibility Analysis  
The costs of this EBP project were minimal. The costs included office supplies and 
printing for the depression screenings tools including labeled folders, laminated copies of the 
depression screening protocol, PHQ-9 interpretation handout, and suggested course of action, 
and paper copies of the PHQ-9’s that were placed in exam rooms. The total costs for the office 
supplies and printing was approximately $150. The project leader provided education to the 
providers at no charge and collected data utilizing an already established EMR. This project was 
very feasible for the dermatology practice and this aided in the implementation of the project.  
Currently depression screening is reimbursed in primary care on an annual basis 
averaging just under $20 per screening per person (Savoy & O'Gurek, 2016). Evidence-based 
guidelines recommend depression screening for all patients with PSO (Burden et al., 2010).  
Unfortunately, reimbursement for depression screenings in specialty care offices is still lacking, 
offering an opportunity for the future in policy change to promote quality comprehensive care. 
Though the project was not targeted to increase financial gain for the practice at this time, the 
EBP project may offer other beneficial aspects including improvement in mental health 
screenings among patients with PSO, enhancements in providing comprehensive care, and 
greater congruency to EBP guidelines for screening depression among patients with PSO. 
Financial benefits may be seen in the future if the providers utilize depression screening long 
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term, or the practice considered utilizing depression screening as part of merit-based incentive 
payment programs. Overall, the potential benefits of this project outweigh the minimal costs.  
Results 
The project leader utilized statistical testing and descriptive statistics to demonstrate the 
results of this project. Based on the pre-intervention retrospective chart reviews, there were a 
total of 57 patients with PSO seen at the office within the 30-day pre-intervention time frame by 
the participating providers. Of these patients with PSO seen at the office pre-intervention, 
providers documented 0 PHQ-9 depression screenings in the EMR. The percentage of patients 
with PSO screened for depression in practice pre-intervention was 0% (Figure 1).    
 
Figure 1. Pre-Intervention Depression Screening for Patients with Psoriasis 
Based on the post-intervention retrospective chart reviews, there were a total of 45 
patients with PSO seen at the office within the 30-day post-intervention time frame by 
participating providers. Of these patients with PSO seen at the office post-intervention, providers 
documented 7 PHQ-9 depression screenings in the EMR. The percentage of patients with PSO 
screened for depression in practice post-intervention was 15.6% (Figure 2).  
0%
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for Patients with Psoriasis   
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Figure 2. Post-Intervention Depression Screening for Patients with Psoriasis 
 In order to evaluate whether this change in screening was statistically significant, the 
project leader applied the Fisher’s exact test to the data. SPSS® results for the Fisher’s exact test 
generated a pre- and post-intervention cross tabulation and a p-value of 0.002 (Table 1).  
Table 1  
Pre- and Post-Intervention Cross Tabulation and Fisher’s Exact Test Results 
       Depression Screening?  P-value 
   No Yes Total   
Pre- Intervention Count 57 0 57  
Percentage (%) 100.0% 0.0% 100%  
Post- Intervention Count 38 7  45  
Percentage (%) 84.4% 15.6% 100%  
  Fisher’s Exact     0.002 
 
 
 
15.6%
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Post-Intervention Depression Screening 
for Patients with Psoriasis  
Patients screened Patients NOT Screened
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Discussion 
 By looking at the results from this EBP project, the number of documented depression 
screenings increased from pre- to post-intervention. Based on the results that 0/57 of the patients 
with PSO were screened for depression prior to the intervention and 7/45 were screened after the 
intervention, there was a 15.6% increase in the overall pre-intervention and post-intervention 
measures for this project.  
 Considering the Fisher’s exact test with an alpha of 0.05, a p = 0.002 caused for the 
rejection of the null hypothesis in favor of the alternative. The null hypothesis stated that no 
change in the number of depression screenings documented for patients with PSO from pre-
intervention to post-intervention would occur (H0: p1 = p2). The alternative hypothesis stated an 
increase in depression screenings documented for patients with PSO from pre-intervention to 
post-intervention would occur (H1: p1 < p2). Based on the p-value of 0.002 generated from the 
Fisher’s exact test and that p = < 0.05, the null hypothesis was rejected and the alternative 
accepted, demonstrating that the change in depression screening was statistically significant.  
The ultimate goal of this project was to encourage practice change. The results from this 
project demonstrated statistical and clinical improvement in depression screening for patients 
with PSO at the target practice. This answers the project’s clinical question supporting that the 
implementation of a screening protocol and education to the providers on the use of the protocol 
did improve the assessment of depression in patients with PSO. Various unforeseen factors arose 
during the implementation of this project and in subsequent paragraphs, the project leader 
considers limitations of this project as well as recommendations for future implementation and 
research considerations.   
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Project Limitations 
 There were limitations to this project. First, the sample size for this project was very 
small totaling only six participating providers who cared for 102 patients with PSO during the 
project’s data collection window: 57 pre-intervention and 45 post-intervention. Because the 
project’s sample size was small, the project design utilized convenience sampling, and the 
project leader did not collect data randomly, the results from this project cannot be generalized.  
Second, shortly after the introduction of the protocol in practice, the practice’s 
administration placed a hold on providers administering the depression screenings as the office’s 
legal advisors considered any legal barriers to implementation. This meant the first four weeks 
following the introduction of the protocol in practice could not be used for data collection as 
originally designed, therefore, the providers may have forgotten some of the content provided in 
the intervention. Providers were notified shortly after the administration agreed to allow the 
project to proceed, but the intervention was not repeated which may have impacted provider 
screening rates.   
Another limitation of the project is that the project did not address how providers adhered 
to any follow-up screening based on the individual PHQ-9 results and protocol 
recommendations. The project looked at a 30-day period after the protocol was introduced to see 
if patients with PSO were screened for depression utilizing the PHQ-9. Documentation of 
depression screening did not require any mentioning of follow up screening. Further studies 
utilizing a similar depression screening protocol should take place over the course of a longer 
time period in order to study adherence to follow-up screening recommendations on a long term 
basis.   
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The final limitation for this discussion was how the data was collected. The data 
collection was reserved for the project leader who manually reviewed charts from visits during 
two 30-day time frames for the participating providers recognizing a diagnosis of PSO and 
whether or not depression screening was documented. The project leader may have missed a 
patient with a diagnosis for PSO or documentation of depression screening. Sorting tools in an 
established EMR may be helpful for similar studies or projects in the future in order to more 
efficiently and effectively review documentation for depression screenings.  
Significance and Implications for Practice 
The results of this project have important implications for the future in relation to 
depression screening for patients with PSO in a dermatology care setting and specifically at the 
project site. While statistically significant improvement in provider screening rates post-
intervention was noted, the project did not address whether or not the screenings were from one 
or multiple providers. It would be beneficial in the future to understand why, if any, providers 
opted not to screen patients for depression in practice. While 15.6% was an improvement in the 
overall percentage of patients with PSO that were screened for depression from pre-intervention 
results, it would also be beneficial to understand why 84.4% were not screened for depression. 
One could hypothesize some barriers including time constraints, provider experience with 
screening for depression, visit priorities, length of the PHQ-9, and many others, but without 
studying provider perceptions of depression screening for this patient population in a 
dermatology care setting, no inferences can be made.  
The project leader recommends future projects or studies to gather insight on the barriers 
to the implementation of depression screening for patients with PSO in a dermatology. Limiting 
barriers to implementation specifically in a dermatology care setting may help to enhance 
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provider assessment of depression in patients with PSO in the future. Another recommendation is 
to utilize a shorter version of the PHQ-9 in the screening protocol, such as the PHQ-2. Screening 
protocols incorporating the PHQ-2 do exist and may offer quicker methods to screening for 
depression in dermatology practice (Korman et al., 2016; McDonald, Shelley, & Jafferany, 
2018).  
The fact that depression screening improved 15.6% post-intervention is important to 
acknowledge, especially when considering implications for practice. Providers did not previously 
screen patients with PSO for depression at the target practice. After the intervention, providers 
engaged in screening which means they likely found screening important or valuable in a clinical 
setting and potentially previously lacked the awareness of the risk of depression in this patient 
population or lacked the tools to screen for depression in dermatology practice. With that being 
said, one must consider how many other dermatology care providers do not screen patients with 
PSO for depression and the importance of spreading awareness for this intervention as well as 
tools for depression screening in other similar settings.  
Sustainability 
This project demonstrated a change in practice from pre- and post-intervention. Whether 
this change in practice will be adopted long term will depend on addressing any barriers to the 
implementation of the protocol at the practice site. This project could be sustainable long term, 
as the costs for implementation are low and the potential for changes to reimbursement for 
depression screening in the future could benefit the practice financially. Furthermore, the project 
leader chose to leave screening materials with the office in hopes that providers would continue 
to utilize the recommended protocol. However, it will be ultimately up the practice’s 
DEPRESSION SCREENING FOR PATIENTS WITH PSORIASIS  45 
administration and the providers as to whether or not they choose to continue to screen patients 
with PSO for depression in practice.  
Dissemination Plan 
 The findings from this project will be disseminated to the practice providers involved in 
this project with a report on the results, the lessons learned, and suggestions for enhanced 
depression screening for patients with PSO. The project leader also seeks to submit a manuscript 
based on this project for publication to a nursing journal specific to dermatology. The project 
leader will also upload this project to the LU’s Digital Commons where it can be accessed online 
around the world. The project leader will continue to seek opportunities to share this project in 
the future and information regarding the importance of assessing patients with PSO for 
depression in practice.  
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Mollon, P., Meng, S., Tian, H., & Shu, M. 
(2017). Economic burden of comorbidities 
in psoriasis patients in the United States: 
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BMC Health Services Research, 171-8. 
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the United 
States. 
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healthcare 
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Golpour, M., Hosseini, S. H., Khademloo, 
M., Ghasemi, M., Ebadi, A., Koohkan, F., 
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psoriasis: A hospital-based case-control 
study. Dermatology Research and Practice, 
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patients with 
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100 patients 
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referred to 
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Beck 
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patients and 
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patients with 
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and anxiety 
who referred 
to the 
psychiatrist 
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questionnaire  
(Y) Psoriatic 
patients reported 
significantly 
higher degrees 
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and anxiety than 
controls 
Hawro, M., Maurer, M., Weller, K., 
Maleszka, R., Zalewska-Janowska, A., 
Kaszuba, A., & ... Hawro, T. (2017). 
Investigate 
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of visible 
115 patients 
with 
Stigmatization 
assessment 
questionnaire, 
Lesions on 
back of hands 
were related to 
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III 
Only hospital 
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gender predispose to stigmatization in 
patients with psoriasis. Journal of the 
American Academy of Dermatology, 76(4), 
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life quality 
index, and 
world health 
quality of life 
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predictor of 
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affected 
psoriasis can be 
debilitating 
Kimball, A., Gladman, D., Gelfand, J., 
Gordon, K., Horn, E.., Korman, N., Korver, 
G., Krueger, G., Strober, B., & Lebwohl, B. 
(2008). National Psoriasis Foundation 
clinical consensus on psoriasis 
comorbidities and recommendations for 
screening. Journal of the American 
Academy of Dermatology, 58(6), 1031-
1042. 
Reviews the 
current 
literature and 
addresses 
what should 
be done with 
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This was an 
expert 
opinion and 
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research 
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means it is 
not as strong 
as a study for 
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clinical 
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including 
depression 
Korman, A. M., Hill, D., Alikhan, A., & 
Feldman, S. R. (2016). Impact and 
management of depression in psoriasis 
patients. Expert Opinion on 
Pharmacotherapy, 17(2), 147-152. 
Reviews 
factors 
relating to 
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patients with 
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Studies 
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PubMed 
and google 
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search of 
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google scholar 
for 
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opinion 
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strength of 
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friendly 
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effect 
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treatment, 
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management 
for 
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and 
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and 
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‘management 
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patients. An 
algorithm was 
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help providers 
screen for 
depression in 
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PHQ-2 and 
PHQ-9 
Korman, N. J., Zhao, Y., Pike, J., & 
Roberts, J. (2016). Relationship between 
psoriasis severity, clinical symptoms, 
quality of life and work productivity among 
patients in the USA. Clinical and 
Experimental Dermatology, 41(5), 514-521. 
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how QoL, 
work 
productivity 
and clinical 
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vary between 
patients with 
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Multivariate 
regression 
was used to 
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relationship 
between 
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Increased 
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severity was 
associated with 
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itching, pain 
and scaling, 
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Patients with 
more severe 
psoriasis 
experienced 
more severe 
symptoms and 
had a greater 
reduction in 
QoL and work 
productivity 
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III 
Patients 
presenting to 
their 
dermatologist 
during the 
study period 
were invited 
to participate 
therefore 
may not 
represent 
non-
consulting 
psoriasis 
population  
(Y) Providers 
must recognize 
the impact of 
severe disease 
on patients 
quality of life 
and take steps to 
address this 
Kouris, A., Christodoulou, C., Efstathiou, 
V., Tsatovidou, R., Torlidi-Kordera, E., 
Zouridaki, E., & Kontochristopoulos, G. 
(2016). Comparative study of quality of life 
and psychosocial characteristics in patients 
Compare the 
quality of 
life, anxiety 
and 
depression, 
240 
participants 
- 80 patients 
with leg 
ulcers, 80 
Quality of 
life, 
depression 
and anxiety, 
loneliness of 
The patients 
with psoriasis 
presented 
statistically 
significant 
Level 
III 
None 
provided 
(Y) Long-term 
(chronic) skin 
diseases 
associated with 
significant 
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with psoriasis and leg ulcers. Wound Repair 
& Regeneration, 24(2), 443-446. 
self-esteem, 
and 
loneliness in 
patients with 
psoriasis and 
leg-ulcer 
patients 
patients 
with 
psoriasis, 
and 80 
healthy 
controls 
were 
included in 
this study 
the patient, 
and self-
esteem were 
assessed using 
four different 
scales 
including the 
Dermatology 
Life Quality 
Index, 
Hospital 
Anxiety and 
Depression 
Scale, UCLA 
loneliness 
scale, and 
Rosenbergs 
Self-esteem 
Scale. 
higher levels of 
loneliness and 
social isolation 
compared to 
leg ulcer 
patients  and 
controls 
impairment of 
the patient's 
quality of life, 
anxiety, and 
self-esteem, 
which are 
frequently 
under-
recognized – 
Implications for 
provider 
awareness and 
care that 
addressing 
psychosocial 
factors 
Lakshmy, S., Balasundaram, S., Sarkar, S., 
Audhya, M., & Subramaniam, E. (2015). A 
cross-sectional study of prevalence and 
implications of depression and anxiety in 
psoriasis. Indian Journal of Psychological 
Medicine, 37(4), 434-440. 
 
Measure the 
prevalence of 
anxiety and 
depression in 
patients with 
psoriasis, 
and to 
correlate 
these with 
severity of 
psoriasis and 
quality of 
life. 
90 
consecutive 
patients of 
psoriasis 
over a 12-
month 
period in a 
tertiary care 
center 
Cross-
sectional 
study – PSA 
index, PHQ-9, 
GAD-& and 
perceived 
stress scale 
used to screen 
for 
depression, 
anxiety, and 
stress 
78.9% had 
depression- 
quality of life 
was worse in 
patients with 
psoriasis and 
comorbid 
anxiety/depress
ion 
Level 
IV 
Small sample 
size, impact 
of treatment 
not assessed  
(Y) Clinically 
significant risk 
for depression, 
anxiety, and 
stress – need to 
consider 
psychological 
and 
dermatological 
factors 
simultaneously  
Lamb, R., Matcham, F., Turner, M., Rayner, 
L., Simpson, A., Hotopf, M., & ... Smith, C. 
(2017). Screening for anxiety and 
depression in people with psoriasis: a cross-
sectional study in a tertiary referral setting. 
British Journal of Dermatology, 176(4), 
1028-1034. 
To screen 
systematicall
y for 
depression 
and anxiety 
in patients 
with 
psoriasis as 
Consecutive 
patients 
attending a 
single, 
tertiary 
centre over 
a 10-month 
period 
PHQ-9, GAD-
3, DLQI 
Regression 
models were 
used to 
identify at-
risk groups for 
The risk of 
MDD or GAD 
was 
significantly 
higher in 
women and 
those with 
severe clinical 
Level 
IV 
Collected 
from one 
single high 
need tertiary 
center 
(Y) Systematic 
screening for 
anxiety and 
depression 
identifies 
clinically 
important levels 
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routine 
clinical 
practice 
psychiatric 
morbidity. 
disease, 
psoriatic 
arthritis and 
previous 
depression/anxi
ety – 9% 
screened 
positive for 
major 
depressive 
disorder 
of depression 
and anxiety 
Loeb, D., Sieja, A., Corral, J., Zehnder, N. 
G., Guiton, G., & Nease, D. E. (2015). 
Evaluation of the role of training in the 
implementation of a depression screening 
and treatment protocol in 2 academic 
outpatient internal medicine clinics utilizing 
the electronic medical record. American 
Journal of Medical Quality, 30(4), 359-366. 
To examine 
if a 
depression 
screening 
protocol and 
training 
would 
enhance 
compliance 
58 
Providers at 
University 
of Colorado 
Internal 
Medicine 
Clinic and 
Lowry 
Internal 
Medicine 
Clinic 
Retrospective 
data analysis - 
to assess  
provider type, 
clinic cite, 
training, and 
documentatio
ns of PHQ-9 
Training was 
positively 
associated with 
documentation 
of PHQ-9 
Level 
IV 
One 
institution, 
participants 
were not 
randomized  
(Y) Offers 
insights into 
real-world 
implementation 
of 
screening/treatm
ent for 
depression 
McDonald, K., Shelley, A., & Jafferany, M. 
(2018). The PHQ-2 in Dermatology-
Standardized Screening for Depression and 
Suicidal Ideation. JAMA 
Dermatology, 154(2), 139-141. 
doi:10.1001/jamadermatol.2017.5540 
 
To provide a 
simple 
approach for 
dermatologis
ts to screen 
and refer 
patients with 
psychiatric 
conditions 
secondary to 
skin disease. 
N/A N/A N/A Level 
VII 
Expert 
opinion – 
lowest level 
of evidence  
(Y) – Suggests 
that 
dermatologists 
and patients can 
benefit from 
screening tool to 
identify 
emotional 
distress 
McIntosh, C. (2017). A depression 
screening protocol for patients with acute 
stroke: a quality improvement project. 
Journal of Neuroscience Nursing, 49(1), 39. 
Determine 
the efficacy 
of an 
evidence-
based 
depression 
screening 
79 
hospitalized 
patients 
with acute 
stroke 
Retrospective 
chart review 
in a 
convenience 
sample  
Implementation 
of a EBP 
depression 
screening and 
treatment 
protocol 
improved early 
Level 
III 
Retrospective 
chart review 
design, short 
implementati
on phase 
(Y) Depression 
screening 
protocols can 
help with early 
diagnosis and 
treatment of 
depression 
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protocol in 
improving 
early 
detection and 
treatment of 
PSD 
detection and 
treatment of 
depression  
Nazik, H., Nazik, S., & Gul, F. C. (2017). 
Body image, self-esteem, and quality of life 
in patients with psoriasis. Indian 
Dermatology Online Journal, 8(5), 343-346. 
Assess 
effects of 
psoriasis on 
QoL, self-
esteem, and 
body image. 
92 patients 
with 
psoriasis 
and 98 
control 
participants 
Socio-
demographic 
characteristics 
were assessed 
with PASI 
scores, results 
from three 
surveys on 
quality of life, 
body image, 
and self-
esteem were 
evaluated 
Self-esteem, 
body image, 
and quality of 
life was found 
to be more 
negatively 
affected in 
psoriasis 
patients over 
control 
Level 
III 
Duration of 
illness, 
Socio-
economic 
status and 
income were 
not 
accounted for 
(Y) links 
psoriasis to 
causing 
psychosocial 
problems 
Pompili, M., Innamorati, M., Forte, A., 
Erbuto, D., Lamis, D. A., Narcisi, A., & ... 
Girardi, P. (2017). Psychiatric comorbidity 
and suicidal ideation in psoriasis, melanoma 
and allergic disorders. International Journal 
of Psychiatry in Clinical Practice, 21(3), 
209-214.  
Examine the 
risk of 
suicide and 
stressful life 
events in a 
sample of 
patients with 
skin disease  
242 
dermatolog
y patients, 
112 
psoriasis, 77 
melanoma, 
53 chronic 
allergies 
Pts were 
administered 
the MINI 
International 
Neuropsychiat
ric Interview, 
Hamilton 
Depression 
Rating Scale, 
Hamilton 
Anxiety 
Rating Scale, 
and the 
Columbia-
Suicide 
Severity 
Rating Scale 
Patients with 
psoriasis were 
more likely to 
have a history 
of psychiatric 
disorders 
compared to 
patients with 
allergies and 
reported past 
suicidal 
ideation as 
compared to 
those with 
melanoma and 
allergies   
Level 
III 
Not provided  (Y) Patients 
affected by 
psoriasis have 
an increased risk 
of psychiatric 
comorbidities 
and suicidal 
ideation 
compared to 
those who have 
other 
dermatological 
disorders 
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Remröd, C., Sjöström, K., & Svensson, Å. 
(2013). Psychological differences between 
early- and late-onset psoriasis: a study of 
personality traits, anxiety and depression in 
psoriasis. British Journal of Dermatology, 
169(2), 344-350. 
Determine 
whether 
patients with 
early-onset 
psoriasis 
differ 
psychologica
lly from 
patients with 
late-onset 
psoriasis, 
regarding 
personality 
traits, 
anxiety and 
depression 
101 
consecutivel
y recruited 
outpatients 
with 
psoriasis  
A descriptive 
cross-
sectional 
study was 
conducted 
Early-onset 
psoriasis (age < 
20 years) were 
significantly 
more anxious 
and depressed 
than patients 
with late-onset 
psoriasis. 
Level 
VI 
A selection 
bias could be 
contributing 
to results 
speculating 
that 
individuals 
with strong 
traits of 
detachment 
would be less 
likely to seek 
medical care 
(Y) Supports 
early diagnosis 
and recognition 
of depression 
and screening 
early on in 
diagnosis  
Richards, H. L., Fortune, D. G., Weidmann, 
A., Sweeney, S. T., & Griffiths, C. M. 
(2004). Detection of psychological distress 
in patients with psoriasis: low consensus 
between dermatologist and patient. British 
Journal of Dermatology, 151(6), 1227-
1233.  
Examine the 
level of 
agreement 
between 
dermatologis
ts and 
patients with 
psoriasis as 
to the 
presence of 
clinically 
significant 
psychologica
l distress 
Forty-three 
consultation
s between 
dermatologi
sts and 
patients 
with 
psoriasis 
were 
assessed 
Consisted of 
two 
assessments 
1) for patients 
1) for 
providers to 
measure 
anxiety and 
depression 
The level of 
agreement 
between patient 
rating and 
dermatologist 
rating as to the 
presence of 
anxiety or 
depression was 
low 
Level 
IV 
Small sample 
size, 
underestimati
on of 
prevalence of 
depression 
(Y) Highlights a 
number of areas 
for improvement 
in the 
psychological 
management of 
patients with 
psoriasis. 
Singh, S., Taylor, C., Kornmehl, H. & 
Armstrong, A. (2017). Psoriasis and 
suicidality: A system review and meta-
analysis. Journal of the American Academy 
of Dermatology, 77(3), 425-440.  
A perform a 
systematic 
review and 
meta-
analysis that 
elucidates 
the 
relationship 
between 
18 studies 
were 
identified  
Systematically 
searched the 
PubMed, 
EMBASE, 
PsycINFO, 
and Cochrane 
databases. 
Searched 
literature 
published 
Subgroup 
analysis 
showed that 
patients with 
psoriasis were 
more likely to 
attempt 
suicides and 
complete 
suicide. Those 
Level I There were 
few studies 
examining 
suicidality in 
conjunction 
with 
psoriasis 
severity 
(Y) Patients 
with psoriasis 
have a 
significantly 
higher 
likelihood of 
suicidal 
ideation, suicide 
attempts, and 
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psoriasis and 
suicidality 
between 1946 
and 2017. 
Applying the 
Preferred 
Reported 
Items for 
Systematic 
Reviews and 
Meta 
Analyses 
guidelines 
younger and 
who psoriasis 
was more 
severe were 
found to be at 
a greater risk.  
completed 
suicides. 
Strober, B., Karki, C., Mason, M., Guo, N., 
Greenberg, J., & Lewohl, M. (2017). 
Comorbidity  
burden and characterization of psoriasis 
patients with concurrent psoriatic arthritis in 
the Corrona psoriasis registry. Journal of 
the American Academy of Dermatology, 
76(6), 
AB77.  http://dx.doi.org/10.1016/j.jaad.201
7.04.314 
 
Characterize 
the PsO 
patients with 
psoriatic 
arthritis 
(PsA) and 
examine 
association 
of outcomes 
with PsA in 
Corrona, a 
prospective 
cohort of 
patients with 
PsO. 
Adult 
patients 
enrolled in 
Corrona as 
of May 31, 
2016  
Multivariate 
logistic 
regression 
was 
conducted to 
examine the 
association of 
other 
comorbidities 
with presence 
of PsA, 
adjusted for 
age, gender, 
body mass 
index (BMI) 
and disease 
duration of 
PsO. 
Psoriasis 
patients with 
PsA had similar 
disease 
severity, 
however, 
reported poorer 
work 
productivity, 
worse pain and 
fatigue and 
were more 
likely to have 
comorbidity 
burden 
compared to 
those who did 
not have 
concurrent PsA 
at enrollment in 
to the registry 
Level 
VI 
Regression 
study  
(Y) Increased 
burden of 
disease in 
patients with 
PsA 
comorbidity  
Suzuki, K., Kumei, S., Ohhira, M., Nozu, 
T., & Okumura, T. (2015). Screening for 
Major depressive disorder with the patient 
health questionnaire in an outpatient clinic 
staffed by primary care physicians in Japan: 
A case control study. Plos ONE, 10(3), 1-8. 
Examine the 
utility of 
PHQ-9 and 
PHQ-2 
574 patients 
for PHQ-9 
and 521 
patients for 
PHQ-2 
Administered 
PHQ-2 and 9  
Forty-two 
patients were 
diagnosed with 
major 
depressive 
disorders 
Level 
IV 
Administered 
in primary 
care only  
(Y) The PHQ-9 
and PHQ-2 were 
useful 
instruments for 
screening for 
major 
depressive 
disorders. 
DEPRESSION SCREENING FOR PATIENTS WITH PSORIASIS  63 
Wojtyna, E., Lakuta, P., Marcinkiewicz, K., 
Bergler-Czop, B., & Brezezinska-Wcislo, L. 
(2016). Gender, body image and social 
support: Biopsychosocial determinants of 
depression among patients with psoriasis. 
Acta Dermato-Venereologica, 97(1), 91-97. 
To examine 
psychosocial 
issues and 
relationship 
to depression 
symptoms in 
patients with 
psoriasis 
219 patients 
with 
psoriasis 
ages 18-70 
yrs old  
Depression, 
appearance, 
social support, 
and distress 
surveys 
utilized, BSA 
index for 
severity of 
psoriasis. 
Multivariate 
logistic 
regression 
analysis was 
performed on 
results.   
 
49.8% of 
participants had 
probable 
depression; 
among those, 
11.9% 
presented 
severe, 18.2% 
moderate and 
19.7% mild 
depressive 
symptoms. as 
defined nearly 
21% of 
respondents 
reported 
suicidal 
thoughts. 
symptoms and 
distress were 
significantly 
higher in 
women than in 
men  
Level 
III 
Some 
participants 
were from a 
psoriasis 
association, 
study was 
cross-
sectional 
(Y) High rates 
of psychological 
impairments in 
patients with 
psoriasis  
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May 11, 2018 
 
Marlee Bryant 
IRB Exemption 3247.051118: Implementation of a Screening Protocol to Improve Provider 
Assessment of Depression in Patients with Psoriasis  
 
Dear Marlee Bryant, 
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with the Office for Human Research Protections (OHRP) and Food and Drug Administration 
(FDA) regulations and finds your study to be exempt from further IRB review. This means you 
may begin your research with the data safeguarding methods mentioned in your approved 
application, and no further IRB oversight is required. 
 
Your study falls under exemption category 46.101(b)(4), which identifies specific situations in 
which human participants research is exempt from the policy set forth in 45 CFR 46:101(b): 
 
(4) Research involving the collection or study of existing data, documents, records, pathological specimens, 
or diagnostic specimens, if these sources are publicly available or if the information is recorded by the 
investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the 
subjects. 
 
Please note that this exemption only applies to your current research application, and any 
changes to your protocol must be reported to the Liberty IRB for verification of continued 
exemption status.  You may report these changes by submitting a change in protocol form or a 
new application to the IRB and referencing the above IRB Exemption number. 
 
If you have any questions about this exemption or need assistance in determining whether 
possible changes to your protocol would change your exemption status, please email us at 
irb@liberty.edu. 
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Depression Screening Protocol 
 
 
Adapted and modified from:  
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Appendix G 
Patient Health Questionnaire-9 
 
 
No permission required to reproduce, display, or distribute. Adapted from patient health 
questionnaire (PHQ) screeners. Retrieved from http://www.phqscreeners.com/sites/g/files/g 
10016261/f/201412/PHQ-9_English.pdf  
 
